Sakar Healthcare Ltd

Fri 18/09/2026,15:53:6 | NSE : SAKAR

₹1179.8050.25 (4.45%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1148.00

Previous Close

₹ 1129.55

Volume

147455

Mkt Cap ( ₹ Cr)

₹ 2625.04

High

₹ 1190.50

Low

₹ 1148.00

52 Week High

₹ 1211.00

52 Week Low

₹ 332.10

Book Value Per Share

₹ 150.44

Dividend Yield

₹ 0.00

Face Value

₹₹10.00

What's Your Call?

Collective community sentiment on Sakar Healthcare Ltd

Your Vote -

Buy

14.29%

Hold

42.86%

Sell

42.86%

14.29%

7 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Sakar Healthcare Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Sakar Healthcare - Analysts/Institutional Investor Meet/Con. Call Updates

    14 Sep 2026, 12:40PM Sakar Healthcare Limited has informed the Exchange about Schedule of meet on 18th Sept., 2026
  • Sakar Healthcare - Analysts/Institutional Investor Meet/Con. Call Updates

    14 Sep 2026, 12:38PM Sakar Healthcare Limited has informed the Exchange about Schedule of meet on 17th Sept., 2026
  • Sakar Healthcare - General Updates

    1 Sep 2026, 12:04PM Sakar Healthcare Limited has informed the Exchange about Sakar receives 14 oncology product new approvals in the EU (Europe), UK & Canada with 7 busin
  • Sakar Healthcare - Copy of Newspaper Publication

    29 Aug 2026, 1:35PM Sakar Healthcare Limited has informed the Exchange about Copy of Newspaper Publication
  • Sakar Healthcare - Shareholders meeting

    27 Aug 2026, 1:24PM Sakar Healthcare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 22, 2026
  • Sakar Healthcare - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Aug 2026, 3:15PM Sakar Healthcare Limited has informed the Exchange about Transcript of Con-Call.
  • Sakar Healthcare - Copy of Newspaper Publication

    1 Aug 2026, 4:13PM Sakar Healthcare Limited has informed the Exchange about Copy of Newspaper Publication
  • Sakar Healthcare - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Jul 2026, 5:10PM Sakar Healthcare Limited has informed the Exchange about Link of Recording
  • Sakar Healthcare - Investor Presentation

    28 Jul 2026, 2:01PM Sakar Healthcare Limited has informed the Exchange about Investor Presentation
  • Sakar Healthcare - Analysts/Institutional Investor Meet/Con. Call Updates

    24 Jul 2026, 8:19PM Sakar Healthcare Limited has informed the Exchange about Schedule of meet/Conference Call.
  • Sakar Healthcare - Press Release

    24 Jul 2026, 8:14PM Sakar Healthcare Limited has informed the Exchange regarding a press release dated July 24, 2026, titled ""Consolidated and Standalone Un-audited Fina
  • Sakar Healthcare - Outcome of Board Meeting

    24 Jul 2026, 12:17PM Sakar Healthcare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
  • Sakar Healthcare - General Updates

    20 Jul 2026, 4:31PM Sakar Healthcare Limited has informed the Exchange about the intimation of Board Meeting for taking on record Unaudited Financial Results for the quar
  • Sakar Healthcare has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    19 Jul 2026, 2:00PM As of June 2026, 52.52% is owned by Indian Promoters and 47.48% by Public. <p align=justify> Top four Promoters holding highest number of shares of Sa
  • Sakar Healthcare - Disclosure under SEBI Takeover Regulations

    9 Jul 2026, 6:51PM Cobra India (Mauritius) Ltdÿ has submitted toÿ the Exchange a copy ofÿDisclosure under Regulation 29(1) of Securities and Exchange Board of Indiaÿ(Sub
  • Sakar Healthcare - General Updates

    8 Jul 2026, 11:18AM Sakar Healthcare Limited has informed the Exchange about Certificate under Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations,
  • Sakar Healthcare - Trading Window

    26 Jun 2026, 3:56PM Sakar Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,

Key fundamentals

Evaluate the intrinsic value of Sakar Healthcare Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 379.8416 360.5158 331.2513 284.677 217.0627
Liabilities 379.8416 360.5158 331.2513 284.677 217.0627
Equity 22.2499 21.9499 21.7499 19.04 17.118
Gross Profit 68.8882 49.6832 38.3635 33.1422 29.4013
Net Profit 30.4846 17.502 11.6709 12.7586 15.2425
Cash From Operating Activities 49.258 34.032 24.4669 33.344 35.7876
NPM(%) 12.1 9.85 7.61 9.56 11.88
Revenue 251.736 177.5847 153.3517 133.359 128.2267
Expenses 182.8478 127.9015 114.9882 100.2168 98.8254
ROE(%) 9.1 5.22 3.48 3.81 4.55

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Sakar Healthcare Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 833.60 -0.58 21.08 0.00 -26.19 0.60
Lotus Eye Hospital and Institute Ltd 115.10 1.75 1644.29 0.00 0.39 0.00
Vaishali Pharma Ltd 8.79 0.11 27.47 0.00 15.42 0.00
Astec Lifesciences Ltd 726.70 -3.77 0.00 0.00 -363.14 0.00

Company Info

The Company was incorporated as ?Sakar Healthcare Private Limited? at Ahmedabad, Gujarat as a private limited company under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated March 26, 2004 bearing corporate identification number U24231GJ2004PTC043861 issued by Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Subsequently, the Company was converted into public company pursuant to shareholders resolution passed in the Extraordinary General Meeting held on March 09, 2015 and the Company was converted into a public limited Company vide fresh certificate of incorporation issued on March 27, 2015 by Registrar of Companies, Gujarat, Ahmedabad and the name of the Company was changed to "Sakar Healthcare Limited". The Corporate Identification Number of the Company is U24231GJ2004PLC043861. Sanjay Shah, Rita Shah and Aarsh Shah are the promoters of the Company. KEY EVENTS AND MILESTONES : The following table sets forth the key events and milestones in the history of the Company, since incorporation: 2004 -Incorporation of the Company. 2005 -The Company received ISO Certification -The Company started commercial production for Plant - 1 which was established for production of Liquid Orals. -The Company started commercially selling its products. 2007 -The Company started exporting its products overseas. 2008 -The Company started commercial production for Plant - 2 which was established for production of Beta Lactum Tablet and Capsules and Dry Syrup B-lactum. / Sachet. -The Company started commercial production for Plant - 3 which was established for production of Liquid Injectibles (SVP) - Ampoules and Liquid Injectibles (SVP) - Vials. 2012 -The Company started commercial production for Plant - 4 which was established for production of Dry Powder Injection. 2015 -Conversion of the Company to a public limited company. 2022-Sakar Healthcare grabed "Pharma Ratna Universe Award - 2022 for  Excellence in Oncology Manufacturing".-Sakar Healthcare entered an agreement with Zydus Life Sciences (Cadila Healthcare) to manufacture Oncology (Anti-Cancer) products.2023-Sakar has entered into a contract for One Patented& Second Inovative Oncology Products development and supply with NDDS for Switzerland based Ferring Pharmaceuticalsand Bazell Pharma'.-Sakar enters an agreement with PharOS (Greece) for development of patent non-infringing Oncology product that ranks amongst top-10 in the segment. 2022 -Sakar Healthcare grabs "Pharma Ratna Universe Award - 2022 for Excellence in Oncology Manufacturing". -Sakar Healthcare enters into an agreement with Zydus Life Sciences (Cadila Healthcare) to manufacture Oncology (Anti-Cancer) products. 2023 -'Sakar has entered into a contract for One Patented & Second Inovative Oncology Products development and supply with NDDS for Switzerland based Ferring Pharmaceuticalsand Bazell Pharma'. -Sakar enters an agreement with PharOS (Greece) for development of patent non-infringing Oncology product that ranks amongst top-10 in the segment. 2024 -'Sakar submitted 20 dossiers of oncology product registration across regions covering Switzerland, Bulgaria, Slovenia, Vietnam, Myanmar & Ethiopia'. 2025-Sakar granted with new NINE, totalling to ELEVEN Marketing Authorization Registration of Oncology products in Europe & Emerging Markets.-Sakar Healthcare Ltd. has informed the Exchange regarding 'Agreements-9 signed across Europe and South (Latin) America to boost up oncology product exports.

The Company was incorporated as ?Sakar Healthcare Private Limited? at Ahmedabad, Gujarat as a private limited company under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated March 26, 2004 bearing corporate identification number U24231GJ2004PTC043861 issued by Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Subsequently, the Company was converted into public company pursuant to shareholders resolution passed in the Extraordinary General Meeting held on March 09, 2015 and the Company was converted into a public limited Company vide fresh certificate of incorporation issued on March 27, 2015 by Registrar of Companies, Gujarat, Ahmedabad and the name of the Company was changed to "Sakar Healthcare Limited". The Corporate Identification Number of the Company is U24231GJ2004PLC043861. Sanjay Shah, Rita Shah and Aarsh Shah are the promoters of the Company. KEY EVENTS AND MILESTONES : The following table sets forth the key events and milestones in the history of the Company, since incorporation: 2004 -Incorporation of the Company. 2005 -The Company received ISO Certification -The Company started commercial production for Plant - 1 which was established for production of Liquid Orals. -The Company started commercially selling its products. 2007 -The Company started exporting its products overseas. 2008 -The Company started commercial production for Plant - 2 which was established for production of Beta Lactum Tablet and Capsules and Dry Syrup B-lactum. / Sachet. -The Company started commercial production for Plant - 3 which was established for production of Liquid Injectibles (SVP) - Ampoules and Liquid Injectibles (SVP) - Vials. 2012 -The Company started commercial production for Plant - 4 which was established for production of Dry Powder Injection. 2015 -Conversion of the Company to a public limited company. 2022-Sakar Healthcare grabed "Pharma Ratna Universe Award - 2022 for  Excellence in Oncology Manufacturing".-Sakar Healthcare entered an agreement with Zydus Life Sciences (Cadila Healthcare) to manufacture Oncology (Anti-Cancer) products.2023-Sakar has entered into a contract for One Patented& Second Inovative Oncology Products development and supply with NDDS for Switzerland based Ferring Pharmaceuticalsand Bazell Pharma'.-Sakar enters an agreement with PharOS (Greece) for development of patent non-infringing Oncology product that ranks amongst top-10 in the segment. 2022 -Sakar Healthcare grabs "Pharma Ratna Universe Award - 2022 for Excellence in Oncology Manufacturing". -Sakar Healthcare enters into an agreement with Zydus Life Sciences (Cadila Healthcare) to manufacture Oncology (Anti-Cancer) products. 2023 -'Sakar has entered into a contract for One Patented & Second Inovative Oncology Products development and supply with NDDS for Switzerland based Ferring Pharmaceuticalsand Bazell Pharma'. -Sakar enters an agreement with PharOS (Greece) for development of patent non-infringing Oncology product that ranks amongst top-10 in the segment. 2024 -'Sakar submitted 20 dossiers of oncology product registration across regions covering Switzerland, Bulgaria, Slovenia, Vietnam, Myanmar & Ethiopia'. 2025-Sakar granted with new NINE, totalling to ELEVEN Marketing Authorization Registration of Oncology products in Europe & Emerging Markets.-Sakar Healthcare Ltd. has informed the Exchange regarding 'Agreements-9 signed across Europe and South (Latin) America to boost up oncology product exports.

Parent Organisation

Sakar Healthcare Ltd.

Founded

26/03/2004

Managing Director

Mr.Sanjay S Shah

NSE Symbol

SAKAREQ

FAQ